Security

Secura Bio is a commercial-stage pharmaceutical company focused on acquiring, developing, and commercializing impactful therapies for the treatment of oncology and hematology. The company's portfolio is anchored by Copiktra (duvelisib), an oral dual inhibitor of PI3K-delta and PI3K-gamma, and Farydak (panobinostat), a histone deacetylase inhibitor. Secura Bio aims to maximize the potential of these established assets through continued clinical development and strategic commercialization efforts. By focusing on late-stage and approved therapies, the company seeks to provide immediate value to patients with high unmet medical needs in the lymphoma and multiple myeloma spaces.